Noseda A - Search Results

1

Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma.

Ramani VC, Zhan F, He J, Barbieri P, Noseda A, Tricot G, Sanderson RD. Ramani VC, et al. Among authors: noseda a. Oncotarget. 2016 Jan 12;7(2):1598-607. doi: 10.18632/oncotarget.6408. Oncotarget. 2016. PMID: 26624982 Free PMC article.

2

Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype.

Ramani VC, Vlodavsky I, Ng M, Zhang Y, Barbieri P, Noseda A, Sanderson RD. Ramani VC, et al. Among authors: noseda a. Matrix Biol. 2016 Sep;55:22-34. doi: 10.1016/j.matbio.2016.03.006. Epub 2016 Mar 22. Matrix Biol. 2016. PMID: 27016342 Free PMC article.

3

Roneparstat: Development, Preclinical and Clinical Studies.

Noseda A, Barbieri P. Noseda A, et al. Adv Exp Med Biol. 2020;1221:523-538. doi: 10.1007/978-3-030-34521-1_21. Adv Exp Med Biol. 2020. PMID: 32274725 Review.

4

Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19.

Xiang J, Lu M, Shi M, Cheng X, Kwakwa KA, Davis JL, Su X, Bakewell SJ, Zhang Y, Fontana F, Xu Y, Veis DJ, DiPersio JF, Ratner L, Sanderson RD, Noseda A, Mollah S, Li J, Weilbaecher KN. Xiang J, et al. Among authors: noseda a. J Virol. 2022 Apr 13;96(7):e0005722. doi: 10.1128/jvi.00057-22. Epub 2022 Mar 23. J Virol. 2022. PMID: 35319225 Free PMC article.

5

The Role of Heparanase in the Pathogenesis of Acute Pancreatitis: A Potential Therapeutic Target.

Khamaysi I, Singh P, Nasser S, Awad H, Chowers Y, Sabo E, Hammond E, Gralnek I, Minkov I, Noseda A, Ilan N, Vlodavsky I, Abassi Z. Khamaysi I, et al. Among authors: noseda a. Sci Rep. 2017 Apr 6;7(1):715. doi: 10.1038/s41598-017-00715-6. Sci Rep. 2017. PMID: 28386074 Free PMC article.

6

Olfaction and Melatonin: The Use of the Olfactory Discrimination Test.

Noseda ACD, Lima MMS. Noseda ACD, et al. Methods Mol Biol. 2022;2550:425-432. doi: 10.1007/978-1-0716-2593-4_41. Methods Mol Biol. 2022. PMID: 36180710

7

MT₂ melatonin receptors expressed in the olfactory bulb modulate depressive-like behavior and olfaction in the 6-OHDA model of Parkinson's disease.

Noseda ACD, Rodrigues LS, Targa ADS, Ilkiw JL, Fagotti J, Dos Santos PD, Cecon E, Markus RP, Solimena M, Jockers R, Lima MMS. Noseda ACD, et al. Eur J Pharmacol. 2021 Jan 15;891:173722. doi: 10.1016/j.ejphar.2020.173722. Epub 2020 Nov 5. Eur J Pharmacol. 2021. PMID: 33159932 Free article.

8

Obstructive sleep apnea and hypopnea syndrome in patients admitted in a tertiary hospital in Cameroon: Prevalence and associated factors.

Poka-Mayap V, Balkissou Adamou D, Massongo M, Voufouo Sonwa S, Alime J, Moutlen BPM, Kongnyu Njamnshi A, Noseda A, Pefura-Yone EW. Poka-Mayap V, et al. Among authors: noseda a. PLoS One. 2020 Jan 16;15(1):e0227778. doi: 10.1371/journal.pone.0227778. eCollection 2020. PLoS One. 2020. PMID: 31945127 Free PMC article.

9

Absence of a synergic nigral proapoptotic effect triggered by REM sleep deprivation in the rotenone model of Parkinson´s disease.

Kmita LC, Ilkiw JL, Rodrigues LS, Targa AD, Noseda ACD, Dos-Santos P, Fagotti J, Trindade ES, Lima MM. Kmita LC, et al. Among authors: noseda acd. Sleep Sci. 2019 Jul-Sep;12(3):196-202. doi: 10.5935/1984-0063.20190078. Sleep Sci. 2019. PMID: 31890096 Free PMC article.

10

Chronic sleep restriction in the rotenone Parkinson's disease model in rats reveals peripheral early-phase biomarkers.

Fagotti J, Targa ADS, Rodrigues LS, Noseda ACD, Dorieux FWC, Scarante FF, Ilkiw JL, Louzada FM, Chowdhury NR, van der Veen DR, Middleton B, Pennings JLA, Swann JR, Skene DJ, Lima MMS. Fagotti J, et al. Among authors: noseda acd. Sci Rep. 2019 Feb 13;9(1):1898. doi: 10.1038/s41598-018-37657-6. Sci Rep. 2019. PMID: 30760786 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

112 results

Search Page